The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Cancer cells, including acute leukemias and myelodysplastic syndromes (MDS), evade apoptosis, a key mechanism for proliferation and chemotherapy resistance.
• Venetoclax, a BCL-2 inhibitor, is approved for treating elderly, unfit acute myeloid leukemia (AML) patients.
• Apoptosis evasion is a critical hallmark of malignancy, driving tumor growth and therapeutic failure.

Purpose of the Study:

• To review pre-clinical and clinical data on apoptosis inhibitors for hematologic malignancies.
• To provide an overview of emerging apoptosis-targeting therapies for AML, ALL, and MDS.
• To highlight the therapeutic potential of inhibiting apoptosis in leukemia and MDS treatment.

Main Methods:

• Literature review of pre-clinical studies.
• Analysis of clinical trial data for apoptosis inhibitors.
• Synthesis of data on BCL-2 family protein inhibitors.

Main Results:

• Apoptosis inhibitors show promise in pre-clinical models of AML, ALL, and MDS.
• Clinical data for venetoclax and other inhibitors demonstrate efficacy in specific patient populations.
• Targeting apoptosis is a viable strategy for overcoming treatment resistance.

Conclusions:

• Apoptosis inhibitors represent a promising therapeutic avenue for hematologic malignancies.
• Further clinical development is warranted for novel apoptosis-targeting agents in AML, ALL, and MDS.
• Inhibition of apoptosis may overcome chemoresistance and improve outcomes in leukemia and MDS.